Skip to main content

Pemfexy FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 21, 2022.

FDA Approved: Yes (First approved February 8, 2020)
Brand name: Pemfexy
Generic name: pemetrexed
Dosage form: Injection
Company: Eagle Pharmaceuticals, Inc.
Treatment for: Non Small Cell Lung Cancer, Malignant Pleural Mesothelioma

Pemfexy (pemetrexed for injection) is a branded alternative to Alimta for the treatment of nonsquamous non-small cell lung cancer and malignant pleural mesothelioma.

Pemfexy is a folate analog metabolic inhibitor indicated:

Development timeline for Pemfexy

Aug  4, 2023Retevmo Demonstrates Superior Progression-Free Survival for Adults with Newly-Diagnosed Non-Small Cell Lung Cancer
Dec 19, 2022Approval Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for Pemfexy in Combination with Pembrolizumab and Platinum Chemotherapy
Feb 10, 2020Approval FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.